|
Linero-Artiaga A., Servos L.M., Rodríguez V., Ruiz J., Karges J. Rationally Designed Ir(III) Complex with an Exceptionally Strong Binding to Human Serum Albumin for Targeted Photodynamic Therapy. Journal of Medicinal Chemistry. 10 April 2025. 68:7792-7806. 10.1021/acs.jmedchem.5c00431
AÑO: 2025; IF: 6.8
|
|
Ortega-Forte E., Rovira A., Ashoo P., Izquierdo-García E., Hally C., Abad-Montero D., Jordà-Redondo M., Vigueras G., Deyà A., Hernández J.L., Galino J., Bosch M., Alberto M.E., Francés-Monerris A., Nonell S., Ruiz J., Marchán V. Achieving red-light anticancer photodynamic therapy under hypoxia using Ir(iii)-COUPY conjugates. Inorganic Chemistry Frontiers. 2025. 10.1039/d4qi03369h
AÑO: 2025; IF: 6.4
|
|
Kasparkova J, Hernandez-Garcia A, Kostrhunova H, Goicuria M, Novohradsky V, Bautista D, Markova L, Santana MD, Brabec V, Ruiz J. Novel 2-(5-Arylthiophen-2-yl)-benzoazole Cyclometalated Iridium(III) dppz Complexes Exhibit Selective Phototoxicity in Cancer Cells by Lysosomal Damage and Oncosis. J Med Chem. 2024 Jan 11;67(1):691-708. doi: 10.1021/acs.jmedchem.3c01978. Epub 2023 Dec 23. PubMed PMID: 38141031; PubMed Central PMCID: PMC10788912.
AÑO: 2024; IF: 6.8
|
|
Ballester FJ, Hernandez-Garcia A, Santana MD, Bautista D, Ashoo P, Ortega-Forte E, Barone G, Ruiz J. Photoactivatable Ruthenium Complexes Containing Minimal Straining Benzothiazolyl-1,2,3-triazole Chelators for Cancer Treatment. Inorg Chem. 2024 Apr 8;63(14):6202-6216. doi: 10.1021/acs.inorgchem.3c04432. Epub 2024 Feb 22. PubMed PMID: 38385171; PubMed Central PMCID: PMC11005040.
AÑO: 2024; IF: 4.7
|
|
Kasparkova J, Novohradsky V, Ruiz J, Brabec V. Photoactivatable, mitochondria targeting dppz iridium(III) complex selectively interacts and damages mitochondrial DNA in cancer cells. Chem Biol Interact. 2024 Apr 1;392:110921. doi: 10.1016/j.cbi.2024.110921. Epub 2024 Feb 19. PubMed PMID: 38382705.
AÑO: 2024; IF: 5.4
|